Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK study of CTP-543 vs Jakafi in healthy volunteers
NCT02960945Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deuruxolitinib in alopecia areata (2 arms), sponsored by Concert Pharmaceuticals. Primary endpoint: Measurement of CTP-543 metabolites and exposure in plasma at 24 hours. Started Nov 2016; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT02960945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960945.